Silver Book Fact

It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall the study finds that the value of increased longevity through these potential innovations will greatly exceed the rising costs of health care.

Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon J, Goldberg R, Dash Y, Muralimohan G
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Recent studies suggest that a low-fat diet which is rich in fruits and vegetables may support brain health. Other studies suggest that remaining socially active and intellectually engaged may also…  
  • Medicaid Costs, 5-Year Delayed Onset  
  • According to the Pharmaceutical Research and Manufacturers of America, every $1 spent on Alzheimer’s research would save Medicare $10 by 2015 and $25 by 2025.  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.